ClinicalTrials.Veeva

Find clinical trials for Multiple Myeloma in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Madrid, MD, ESP:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen
Janssen

Madrid, Spain and 145 other locations

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing multiple my ...

Enrolling
Smoldering Multiple Myeloma (SMM)
Drug: Linvoseltamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Madrid, Spain and 7 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Madrid, Spain and 49 other locations

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Lenalidomide
Drug: carfilzomib

Phase 2

PETHEMA Foundation

Madrid, Spain and 15 other locations

Status recently updated

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Enrolling
Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Dexamethasone

Phase 2

AbbVie
AbbVie

Madrid, Spain and 31 other locations

after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...

Enrolling
High-Risk de Novo Multiple Myeloma
Drug: Teclistamab
Drug: Lenalidomide

Phase 2

PETHEMA Foundation

Madrid, Spain and 9 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Madrid, Spain and 119 other locations

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...

Enrolling
Multiple Myeloma
Drug: ABBV-383

Phase 1

TeneoOne

Majadahonda, Madrid, Spain and 27 other locations

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Madrid, Spain and 156 other locations

with BMS-986405 in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study ...

Active, not recruiting
Multiple Myeloma
Drug: CC-99712
Drug: BMS-986405

Phase 1

Celgene
Celgene

Madrid, Spain and 19 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems